Skip to main content

Peer Review reports

From: Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

Original Submission
20 Apr 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
27 May 2022 Reviewed Reviewer Report
31 May 2022 Reviewed Reviewer Report
29 Jun 2022 Author responded Author comments - Feng Chen
Resubmission - Version 3
29 Jun 2022 Submitted Manuscript version 3
2 Jul 2022 Author responded Author comments - Feng Chen
Resubmission - Version 4
2 Jul 2022 Submitted Manuscript version 4
14 Jul 2022 Reviewed Reviewer Report
22 Jul 2022 Reviewed Reviewer Report
6 Aug 2022 Author responded Author comments - Feng Chen
Resubmission - Version 5
6 Aug 2022 Submitted Manuscript version 5
8 Aug 2022 Author responded Author comments - Feng Chen
Resubmission - Version 6
8 Aug 2022 Submitted Manuscript version 6
24 Aug 2022 Reviewed Reviewer Report
29 Aug 2022 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
31 Aug 2022 Editorially accepted
29 Sep 2022 Article published 10.1186/s12885-022-10046-z

You can find further information about peer review here.

Back to article page